Evolocumab

Higher Lipoprotein(a) Marks Greater Coronary Risk Without Prior MI or Stroke, While Evolocumab Delivers Similar Relative Benefit and Larger Absolute Gains

In VESALIUS-CV, elevated baseline Lp(a) independently predicted major coronary events, especially MI, in patients without prior MI or stroke. Evolocumab reduced relative risk similarly across Lp(a) levels, with numerically greater absolute